Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021


Target Audience

This activity is intended for cardiologists, heart failure specialists and allied healthcare professionals.

Release / Expiration Date

November 4, 2021 – November 4, 2022

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate. 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify patients likely to benefit from invasive procedures versus pharmacological treatment

• Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Faculty Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. 

The following financial relationships have been provided:

Consultant: Pfizer, Sanofi Genzyme

Speakers Bureau: Sanofi Genzyme

Advisory Board: AstraZeneca, MyoKardia

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: SGLT-2 inhibitors (empaglifozin and dapaglifozin) in non-obstructive hypertrophic cardiomyopathy, Mavacamten in obstructive hypertrophic cardiomyopathy, Tafamidis in transthyretin amyloid cardiomyopathy, Phospholamban in murine cardiomyopathy, SGLT-2 inhibitors in cardiomyopathy.

Staff and Reviewer Disclosures

ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Terms and Conditions


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
Course opens: 
Course expires: 

Professor Perry Elliott
Chair of Cardiovascular Medicine,University College London, President Cardiomyopathy UK

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
Please login or register to take this course.